A UK study has suggested that a 10-minute MRI scan is more effective at detecting prostate cancer than testing for blood levels of the biomarker PSA, picking up serious ca
Ipsen and Exelixis could expand the use of blockbuster oncology drug Cabometyx into prostate cancer, based on data from a phase 3 study – and help bring a cancer immunothe
Johnson & Johnson has been given FDA approval for Akeega, a combination tablet for first-line treatment of adults with BRCA-positive metastatic castration-resistant pr
In this episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with André Deschamps, formerly president of Europa Uomo, the voice of men with prostate cancer in Europe.
The devolved Welsh Government plans to expand the use of an artificial intelligence-powered tool used to spot cancer in biopsy samples, after seeing a 13% increase in pros
Pfizer has won FDA approval for its PARP inhibitor Talzenna in castration-resistant prostate cancer (CRPC) in a combination that it hopes will help it challenge AstraZenec